公开(公告)号：EP2066346B1

公开(公告)日：2019-07-03

申请号：EP07872297.2

申请日：2007-09-12

申请人： AlphaVax, Inc.

发明人： SMITH, Jonathan F. ,  HUBBY, Bolyn ,  BERGLUND, Peter ,  COPP, Laura ,  ELLIS, Whitney

IPC分类号： A61K39/145

公开(公告)号：EP2947149A1

公开(公告)日：2015-11-25

申请号：EP15173487.8

申请日：2008-06-20

申请人： Alphavax, Inc.

发明人： KAMRUD, Kurt I. ,  SMITH, Jonathan F. ,  MAUGHAN, Maureen

IPC分类号： C12N15/63 ,  C12N15/40 ,  C07K14/705 ,  A61K38/00 ,  C12N15/86 ,  A61K39/12 ,  A61K39/00 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5256 ,  C12N2710/24134 ,  C12N2770/36134 ,  C12N2770/36143

摘要： The present invention provides use of an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins in inducing an immune response in a subject or for use in immunizing a subject or for treating a subject.

摘要翻译： 本发明提供分离的RNA分子的用途，其包括：a）甲病毒5'复制识别序列，其中至少一个起始密码子已经从5'复制识别序列中除去; b）编码甲病毒结构蛋白的核苷酸序列; 和c）甲病毒3'复制识别序列，条件是RNA分子不含有指导（b）的核苷酸序列的转录的启动子，并且其中（a）的甲病毒5'和3'复制识别序列 ）和（c）在甲病毒非结构蛋白存在下RNA受体的直接复制以诱导受试者中的免疫应答或用于免疫受试者或用于治疗受试者。

公开(公告)号：EP2066346A2

公开(公告)日：2009-06-10

申请号：EP07872297.2

申请日：2007-09-12

申请人： AlphaVax, Inc.

发明人： SMITH, Jonathan F. ,  HUBBY, Bolyn ,  BERGLUND, Peter ,  COPP, Laura ,  ELLIS, Whitney

IPC分类号： A61K39/145

CPC分类号： A61K39/39 ,  A61K38/208 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55538 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/16634 ,  C12N2760/16134 ,  C12N2760/16234 ,  C12N2770/36143

摘要： The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.

摘要翻译： 可以通过同时施用表达白细胞介素-12的甲病毒复制子颗粒来增强对纯化形式的目的抗原或通过甲病毒复制子颗粒表达的免疫应答。 这允许使用显着更小量的抗原，并且该免疫策略也可以消除对加强抗原的施用的需要，或者可以减少对抗原的有效免疫应答所需的加强次数。

公开(公告)号：EP2947149B1

公开(公告)日：2018-02-28

申请号：EP15173487.8

申请日：2008-06-20

申请人： Alphavax, Inc.

发明人： KAMRUD, Kurt I. ,  SMITH, Jonathan F. ,  MAUGHAN, Maureen

IPC分类号： C12N15/63 ,  C12N15/40 ,  C07K14/705 ,  A61K38/00 ,  C12N15/86 ,  A61K39/12 ,  A61K39/00 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5256 ,  C12N2710/24134 ,  C12N2770/36134 ,  C12N2770/36143

摘要： The present invention provides use of an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins in inducing an immune response in a subject or for use in immunizing a subject or for treating a subject.

公开(公告)号：EP2183368B1

公开(公告)日：2016-08-10

申请号：EP08825920.5

申请日：2008-06-20

申请人： Alphavax, Inc.

发明人： KAMRUD, Kurt I. ,  SMITH, Jonathan F. ,  MAUGHAN, Maureen

IPC分类号： C12N15/63 ,  C12N15/40 ,  C07K14/705 ,  A61K38/00

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5256 ,  C12N2710/24134 ,  C12N2770/36134 ,  C12N2770/36143

公开(公告)号：EP2183368A2

公开(公告)日：2010-05-12

申请号：EP08825920.5

申请日：2008-06-20

申请人： Alphavax, Inc.

发明人： KAMRUD, Kurt I. ,  SMITH, Jonathan F. ,  MAUGHAN, Maureen

IPC分类号： C12N15/63 ,  C12N15/40 ,  C07K14/705 ,  A61K38/00

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5256 ,  C12N2710/24134 ,  C12N2770/36134 ,  C12N2770/36143

摘要： The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.